Cellectar Biosciences, Inc. Q2 2025 Earnings Recap

Cellectar Biosciences reported a strong second quarter, showcasing strategic advances in its clinical pipeline and regulatory strategies while securing additional funding to support future initiatives.

Key Takeaways

• Submitted a new drug application for iopofosine I-131 for Waldenstrom's Macroglobulinemia under an accelerated approval pathway, emphasizing commitment to expedite treatment for rare diseases.
• Secured €5.8 million in financing, boosting cash reserves to $11 million, sufficient to fund operations through Q2 2026.
• Advanced discussions with potential partners to secure non-dilutive capital and expertise for iopofosine's global commercialization.
• Research and development expenses significantly decreased to $2.4 million due to completed patient enrollment in the CLOVER-WaM study.
• Timeline established for initiating a Phase I trial of CLR 125 in late 2025 or early 2026, expanding the company's radiopharmaceutical offerings.